4DMedical.
Lung imaging software with real clearances and real cash. The valuation is where it gets difficult.
A$3.10 (-5.64% on the day) · Market cap about A$1.86bn (BG Trading estimate) · 30 October 2026
The story in 60 seconds.
A real product with fast growth and a big cash pile, priced at 228 times revenue while the chart breaks down. Tap any card to jump to the detail.
A scan you already have, read in a new way.
Software sites, up 77% on a year ago and up 34% since 30 June.
4DMedical (ASX: 4DX) sells software that turns an ordinary chest CT scan into a map of how well each part of the lung is breathing. Its main product, CT:VQ, does this without contrast dye or a nuclear medicine scan. Hospitals pay for the analysis as software as a service. The company reports a gross margin of 93%.
It earns from three places: per-scan software revenue from hospitals and imaging groups, distribution through Philips in the US and Canada, and research and pharma contracts (a one-year GSK contract started on 1 May 2026). Sales sit mostly in the US, with clearances also held in Europe, the UK, Canada, Australia, New Zealand and Brazil. [Reported fact, 4DMedical 2026 Annual Report]
Why now
The share price has fallen about 59% from the April high of A$7.55 to A$3.10, and the stock lost 5.64% today. At the same time the business keeps growing. Sites rose from 540 at 30 June to 724 at 30 September, and September quarter revenue was up 66%. [Reported fact; price from chart; drawdown is a BG Trading calculation]
What the market may be missing
US Medicare pays US$650.50 per CT:VQ scan, yet 4DX reported only about A$21 of revenue per scan analysed in FY26 (A$7.1m over 344,075 scans, our calculation). How much of the reimbursed amount reaches 4DX through its partners will decide how large this business can become. The company has not broken that down.
On the other side, the cash balance covers roughly four years at the current spending rate (our estimate), which is longer than the market usually credits a stock that has fallen this far.
Competitive advantage
Rating: NARROW, confidence MEDIUM. [Inference]
- FDA clearance for CT:VQ in September 2025, plus clearances across several markets (table below). [Reported fact]
- US Medicare reimbursement of US$650.50 per scan gives hospitals a reason to adopt. [Reported fact]
- A 93% gross margin points to real pricing power in the software. [Reported fact]
- Revenue is only A$7.1m, so the moat has not yet shown up in the numbers.
- Several of the large contracts are described as early pilots or one-year terms.
- Patent coverage and expiry dates: not found.
Tiny revenue. Big costs.
Revenue is growing, but the operating loss is eight times larger.
FY26 revenue grew 21% to A$7.1m. That is a small base. The company still spends about A$57m more than it earns at the operating line, and the operating loss widened from A$47.5m. We rate earnings quality LOW: sales are tiny against costs, half of total income is other income, and the statutory loss is inflated by items we could not trace. [Inference]
| Metric | FY26 (30 Jun 26) | FY25 (30 Jun 25) | Change | Read |
|---|---|---|---|---|
| Operating revenue | A$7.1m | A$5.85m | +21% | Slower than the Q1 FY27 jump of 66% |
| Gross margin | 93% | 92% | +1 pt (approx.) | Software economics are excellent |
| Total income (incl. other income) | A$14.6m | not sourced | n/a | A$7.5m is other income, not sales |
| Operating loss | -A$57.5m | -A$47.5m | -21% | Costs are growing faster than sales |
| Statutory net loss | -A$204.4m | -A$30.1m | % not meaningful | The A$174m gap is not itemised in the sources we could read. Verify in the filing. |
| EPS | -38c | -7c | n/a | |
| Operating cash flow | -A$31.3m | -A$34.5m | +9% better | Cash burn improved in FY26 |
| Free cash flow | -A$32.2m | -A$34.6m | +7% better | |
| Cash | A$278.0m | A$6.9m | n/a | Funded by A$233m of placements |
| Debt (aggregator figure) | A$180.2m | A$4.3m | n/a | Composition not verified |
| Cash less the unverified A$180.2m | A$97.8m | A$2.6m | n/a | Shown both ways, see section 3 |
| ROE (average equity) | -174% | n/a | n/a | BG Trading calculation |
| ROIC | not meaningful | Negative operating profit | ||
| Scan analyses | 344,075 | 194,789 | +77% | Reported |
| Sites | 540 | 388 | +39% | Reported |
| Backlog / minimum commitments | Philips minimum about A$15m over CY26-27 | Total backlog not disclosed |
Sources: 4DMedical 2026 Annual Report (revenue, margin, sites, scans, total income); StockAnalysis.com aggregator data for operating loss, net loss, cash flow and balance sheet (not yet checked against the full financial statements). Quarter: Q1 FY27 is unaudited.
Cash in. Cash out.
Cash at 30 September, with about four years of runway at today’s spending.
Cash was A$278.0m at 30 June and A$242.8m at 30 September. The fall of A$35.2m in one quarter includes A$18.0m paid to complete the contextflow acquisition and A$4.9m for a 10% stake in RevealDx. Operating cash outflow was A$15.2m in the quarter, of which A$0.8m was one-off. [Reported fact, Q1 FY27 activity report]
Strip out the one-off and the quarterly burn is about A$14.4m, or A$57.6m a year. At that rate the cash lasts about 4.2 years (BG Trading estimate). The quarterly burn is also nearly double the FY26 average of A$7.8m a quarter, so the runway is shorter than it looks if costs keep climbing.
Dilution: shares on issue rose about 28% in FY26 (from 465.5m to 597.6m), and the company raised A$150m and A$83m in placements, with Pro Medicus investing A$10m. The share price now sits below both placement prices (A$3.80 and A$5.90), which can leave a supply overhang. [Reported fact and BG Trading calculation]
The growth is real.
Scan analyses in the September quarter, with 724 sites live.
September quarter revenue was A$2.3m, up 66%. Scan analyses were 119,672 (up 61% on the year) and sites reached 724. Gross margin stayed above 90%. FY26 revenue growth was 21%, so revenue growth is accelerating. Scan growth has eased from 77% in FY26 to 61%. [Reported fact]
- Philips has a minimum order commitment of about US$10m (A$15m) across calendar 2026 and 2027, about 2.1 times FY26 revenue spread over two years (BG Trading calculation). [Reported fact]
- Mayo Clinic, GSK and a US Veterans Affairs network have signed on in 2026.
- The Veterans Affairs deal is worth about US$0.8m over five years, with annual extensions rather than a firm commitment.
- Revenue per scan is about A$19 in the September quarter, down from A$21 in FY26 (our calculation). Volume is growing slightly slower than revenue, so the price per scan is not rising yet.
Backlog Coverage: total backlog is not disclosed. Pipeline, pilots and distribution agreements are not counted as contracted revenue.
What it has to deliver.
Our base case revenue for FY27, about 70% above FY26.
FY26 is fully reported, so this is the FY27 projection. All three scenarios are BG Trading estimates. The company has given no numerical guidance for FY27 (qualitative only). [Management guidance: none; Analyst consensus: not sourced]
| Scenario | FY27 revenue | Assumption | Needed in the remaining three quarters |
|---|---|---|---|
| Bear | A$9.0m | Revenue stays near the Q1 run rate (A$2.3m a quarter) | About A$2.2m a quarter |
| Base | A$12.0m | Growth of about 70%, in line with the Q1 pace, helped by Philips volumes | About A$3.2m a quarter (+41% on Q1) |
| Bull | A$16.0m | US adoption accelerates and pricing per scan rises | About A$4.6m a quarter (+99% on Q1) |
With A$2.3m already booked, our base case needs the next three quarters to average A$3.2m, which is 41% above the September quarter. We rate the base case REQUIRES STRONG EXECUTION.
Beyond FY27
The company points to a larger market after its CLEAR study: about US$1.1bn initially addressable in the US, rising to about US$3bn if the study succeeds (management view). We have not modelled FY28 because there is no guidance and no consensus to anchor on. [Management guidance]
Macro and industry
Macro: NEUTRAL. Industry: EXPANDING, as hospitals adopt AI imaging tools and reimbursement for lung scans spreads. The single variable that matters most is how many reimbursed US scans turn into 4DX revenue, and at what price per scan. [Inference]
Priced for the dream.
Enterprise value is 228 times FY26 revenue.
| Metric | Value | Working |
|---|---|---|
| Market cap | A$1.86bn | A$3.10 x 601.6m shares (shares at 30 Jun 2026; BG Trading estimate) |
| Enterprise value | A$1.62bn | Market cap less A$242.8m cash at 30 Sep. A$1.80bn if the unverified A$180.2m is debt |
| EV / Revenue (FY26) | 228x | A$1,622m / A$7.1m. 254x including the unverified liability |
| EV / Revenue (Q1 annualised) | 176x | A$1,622m / A$9.2m |
| P/S | 263x | A$1,865m / A$7.1m |
| P/B | 11.0x | A$1,865m / A$170.2m equity at 30 Jun |
| P/E, Fwd P/E, PEG | not meaningful | Earnings are negative |
| EV / EBITDA | not meaningful | EBITDA not reported, operating loss of A$57.5m |
| FCF yield | -1.7% | -A$32.2m / A$1,865m |
| Dividend yield | 0% | No dividend |
We classify the valuation as EXTREMELY EXPENSIVE. To bring the multiple down to Pro Medicus’s level (78x revenue), 4DX would need about A$20.7m of revenue, roughly three times FY26. To reach 20x, a multiple still above most medtech, revenue would need to reach about A$81m. [BG Trading estimate]
Peer comparison is in section 8.
One big test ahead.
The CLEAR clinical readout is the event that could change the size of the market.
| Horizon | Catalyst | Rating | Status |
|---|---|---|---|
| 0 to 3 months | December quarter activity report (due around end January 2027) | HIGH | Confirmed event, outcome open |
| 3 to 6 months | Half year results for FY27 (expected February 2027, date not confirmed) | HIGH | Confirmed event, date to verify |
| 6 to 12 months | US adoption of CT:VQ under Medicare, Philips order flow, hospital pilots turning into contracts | MEDIUM | Speculative |
| 12 to 24 months | CLEAR clinical readout (company target: calendar 2027) | VERY HIGH | Speculative outcome |
| Risk | Probability | Impact | Why |
|---|---|---|---|
| Fundamental | High | High | Operating loss widening faster than revenue |
| Valuation | High | High | 228x revenue leaves little room for a miss |
| Technical | High | Medium | Price is below its 9, 40 and 250 day averages |
| Financial | Low | Medium | Cash is strong, but burn is rising and the A$180.2m liability needs checking |
| Execution | Medium | High | Base case needs 41% more revenue per quarter than today |
| Industry | Medium | Medium | Competing AI imaging tools and reimbursement changes |
| Macro | Medium | Low | Not a main driver for this stock |
| Governance | Low | Medium | No specific issue found in our sources |
| Dilution | High | High | Shares up 28% in FY26, A$233m of placements, price below both placement prices |
Greatest risk of permanent capital loss: valuation compression if the revenue ramp slips, because at 228x revenue a single disappointing quarter can reprice the stock. [Inference]
Dearer than the dearest.
EV to revenue: 4DX against Pro Medicus, PolyNovo and Nanosonics.
All figures are for the year to 30 June 2026 unless stated. Enterprise value is market cap less cash plus debt, a BG Trading estimate. *Unverified aggregator debt, excluded from 4DX EV. **PolyNovo cash is from its July trading update, debt not disclosed, so its EV may be understated. Peer market caps use share counts from TipRanks (PNV), Investing.com (NAN) and StockAnalysis.com (PME, 4DX) and are BG Trading estimates.
| Company | FY end | Price | Market cap | Cash / debt | EV | Revenue FY26 | EBITDA (or EBIT) | NPAT / loss | EV / Revenue | Analyst view |
|---|---|---|---|---|---|---|---|---|---|---|
| 4DX | 30 Jun | A$3.10 (30 Oct) | A$1,865m | A$242.8m / A$180.2m* | A$1,622m | A$7.1m | n/m | -A$204.4m | 228x | Hold (3). Broker price target A$4.37 (+41%) |
| Pro Medicus (PME) | 30 Jun | A$198.41 (27 Oct) | A$20,730m | A$252.3m / nil | A$20,478m | A$261.7m | EBIT A$196.1m | A$144.7m | 78x | Buy (15). Target A$202.61 (+2.1%) |
| PolyNovo (PNV) | 30 Jun | A$0.895 (22 Oct) | A$618m | A$35.4m** / not disclosed | A$583m | A$150.0m | A$12.1m | A$7.3m | 3.9x | Mixed. Consensus A$1.21 (+35%) |
| Nanosonics (NAN) | 30 Jun | A$3.10 (26 Oct) | A$913m | A$155.2m / nil | A$758m | A$203.9m | EBIT A$16.0m | not disclosed | 3.7x | Hold to Buy. Consensus A$3.63 (+17%) |
Growth and profit. Revenue growth was 21% for 4DX in FY26 (66% in the September quarter), against 22.9% for Pro Medicus, 16.1% for PolyNovo and 3% for Nanosonics. 4DX is the only one losing money at the operating line. Pro Medicus runs a 75% EBIT margin, PolyNovo has A$12.1m of EBITDA and Nanosonics has A$16.0m of EBIT.
Multiple against growth. EV/Revenue divided by growth is about 10.9 for 4DX on FY26 growth, 3.4 for Pro Medicus, 1.2 for Nanosonics and 0.24 for PolyNovo. Using the faster Q1 growth rate narrows 4DX to about 3.5, in line with Pro Medicus, but Pro Medicus earns very high profits and 4DX does not. [BG Trading calculation]
The most important difference: Pro Medicus pays for its multiple with profit, 4DX asks you to pay for it with future profit.
Is (ASX: 4DX) 4DMedical Limited, undervalued or overvalued in comparison to its peers?
OVERVALUED versus peers. [Inference]
- EV/Revenue of 228x is a 192% premium to Pro Medicus (2.9 times its multiple) and about 60 times the multiples of Nanosonics and PolyNovo.
- 4DX has no positive EBITDA or earnings, so EV/EBITDA and P/E cannot support the premium.
- The fastest recent revenue growth of the group (66% in Q1) and more than 90% gross margin explain part of the premium.
- Broker coverage is thin: 3 analysts, Hold, with a A$4.37 price target set before this week’s fall.
The gap does not look fully earned. This is a relative call: the peer group is itself richly priced at the top (Pro Medicus), so even a smaller premium would still leave 4DX expensive in section 6. Confidence: PME high, NAN medium, PNV low.
Oversold, at the floor.
RSI sits at the lowest reading of the six month range, right on the range floor.
- Trend and moving averages. Price is A$3.10, about 18% below the 250 day average (A$3.79) and about 12% below the 9 day average (A$3.52). The 40 day average is not labelled on the chart, but its line sits above the price. The long-term picture is still up from the November 2025 low, but the six month range has been broken at the short end. This puts price in the technically discounted band (10% to 30% below the 250 day), which is a technical measure and not a fundamental valuation.
- Support and resistance. The floor of the six month range is the A$3.00 to A$3.15 band, tested several times since May and again today. A larger zone sits at about A$2.10 to A$2.25. Resistance is at about A$4.40 to A$4.50 (the October high) and A$4.80 to A$5.00, with the April peak near A$7.55.
- RSI. At 24.4 it is oversold. It has been rejected five times by a falling resistance line, and it is sitting on a rising support line. Price is making similar lows while RSI is making higher lows, a mild positive divergence that has not yet been confirmed by price.
- Volume. The latest bar is light, so there is no sign yet of capitulation or heavy buying. The sell-off has come on far less volume than the March and April spike.
- Structure. Lower highs (A$4.90 in August, A$4.50 in October) and a break below all three averages. We classify price structure as DETERIORATING.
Probability view
Qualitative judgment from the chart structure, not statistical forecasts.
BGS 20 VIEW: Watchlist.
Positioning: This area is only available for VIP Members, click here to Subscribe.
Great technology. Not a great price.
BGS 20 Score. Business Quality 61, Setup Quality 28.
A good company, a good stock and a good entry are three different questions.
BGS 20 Score: 43/100 (Business Quality 61, Setup Quality 28). Business Quality and Setup Quality differ by 33 points: a real product with a strong cash position, in a set-up that is expensive and technically weak.
| Category | Score | Weight | Weighted |
|---|---|---|---|
| Fundamentals | 35 | 15% | 5.25 |
| Growth | 72 | 10% | 7.20 |
| Balance sheet | 78 | 10% | 7.80 |
| Valuation | 8 | 20% | 1.60 |
| Technical | 35 | 10% | 3.50 |
| Catalysts | 60 | 10% | 6.00 |
| Industry and macro | 70 | 10% | 7.00 |
| Risk / reward (assessed in VIP) | 30 | 15% | 4.50 |
| BGS 20 Score | 100% | 42.85, rounded to 43 |
Working: Business Quality = (35×15 + 72×10 + 78×10 + 70×10) / 45 = 60.6. Setup Quality = (8×20 + 35×10 + 60×10 + 30×15) / 55 = 28.4. No cap applied. No Reversal Watch points added, because RSI divergence alone, without a confirming price signal, is not enough. Biggest factor lifting the score: the balance sheet. Biggest factor lowering it: valuation.
Bull, base and bear cases
| Case | Fair value per share | Assumption |
|---|---|---|
| Bear | A$1.00 | Revenue stays near A$9m and the multiple halves from Pro Medicus levels (40x) |
| Base | A$1.96 | FY27 revenue A$12m at Pro Medicus’s 78x EV/revenue plus cash |
| Bull | A$2.48 | FY27 revenue A$16m at 78x plus cash |
Fair value is built from our FY27 revenue scenarios (BG Trading estimates), a 78x EV/revenue multiple for base and bull (the Pro Medicus level, the richest in the group) and 40x for bear, plus cash of A$242.8m, divided by 601.6m shares. It is a qualitative range, not a price target. Current price vs base fair value: (1.96 – 3.10) / 3.10 = -37%.
| Item | Detail |
|---|---|
| Company | 4DMedical Limited |
| Ticker | ASX: 4DX |
| Price | A$3.10 (30 Oct 2026) |
| Market cap | About A$1.86bn (BG Trading estimate) |
| BGS 20 level | Technically discounted, 18% below the 250 day average |
| Long-term fair value (base) | A$1.96 (BG Trading estimate, not a price target) |
| Upside to fair value | -37% |
| Bull / bear probability | 30% rebound / 45% break lower (qualitative) |
| Score | 43/100 (Business Quality 61, Setup Quality 28) |
| Valuation | Extremely expensive |
| Technical position | Watchlist, deteriorating structure |
| Fundamental and growth trend | Growth accelerating, losses widening |
| Balance sheet | Strong, subject to the A$180.2m check |
| Earnings quality | Low |
| Macro | Neutral |
| Risk level | Extreme speculative |
| Suitability | Aggressive investors only |
| Rating | AVOID (score below 50) |
Buy at the current price? Sign up for VIP membership to see this part.
- Biggest reason to own: a cleared, reimbursed product, 66% revenue growth and about four years of cash.
- Biggest reason not to own: 228x revenue, with an operating loss that is eight times revenue.
What invalidates the thesis: revenue per scan failing to rise, quarterly burn continuing to climb, or the CLEAR study missing. The exact chart levels are in the VIP area.
Single most important catalyst: the CLEAR clinical readout (calendar 2027). Main driver: valuation and catalysts. Asymmetric risk/reward: assessed in the VIP area. Discounted? Technically discounted, fundamentally expensive. Trade or long-term: a speculative position, not a core holding.
SHOULD I BUY (ASX: 4DX) NOW?
ENTRY DETAILS, TRADING CONSIDERATIONS, TARGETS, SHAREHOLDER STATISTICS, HOLDING TREND (VIP AREA)
VIP Members only. Our entry price, targets, stop loss and shareholder statistics are for VIP Members.
Sources
4DMedical 2026 Annual Report (4dmedical.com); 4DMedical Q1 FY27 activity report (28 October 2026) as reported by Kalkine; StockAnalysis.com (4DX and PME financials, price, balance sheet and analyst data); TipRanks (ownership, PolyNovo statistics); The Bull (7 May 2026) and IBTimes Australia (July 2026) for the 2026 share price history and placements; Pro Medicus FY26 results (18 August 2026) via Market Index; Nanosonics FY26 results (ASX announcement, 25 August 2026); PolyNovo FY26 trading update (23 July 2026) and results (ASX announcement, 26 August 2026); FNArena (NAN and PNV consensus); Investing.com and InvestSmart (Nanosonics share data); company images supplied by BG Trading; chart supplied by BG Trading.
Figures marked as BG Trading estimates are our calculations and may differ from other sources. Prices are from the dates shown and will have moved.
Disclaimer. The information contained in this report is provided by BG Trading Australia (ACN 161943228, License 4901880) for general informational purposes only and does not constitute personal financial product advice. It has been prepared without taking into account your objectives, financial situation, needs, or risk tolerance, and should not be relied upon as a substitute for independent professional advice tailored to your circumstances. Nothing in this report constitutes an offer, solicitation, or recommendation to buy, sell, or hold any financial product.
All technical levels, targets, and commentary reflect a point-in-time interpretation of publicly available chart data and are inherently speculative; markets are volatile and unpredictable, and no methodology, including the BGS 20 framework, can guarantee any particular outcome. Past performance is not, and should not be treated as, an indicator of future performance. To the maximum extent permitted by law, BG Trading Australia, its directors, employees, and agents disclaim all liability, whether direct or indirect, for any loss or damage arising from reliance on this report, including any errors, omissions, or inaccuracies in the information provided, and any decision made or action taken on the basis of it. You acknowledge that trading and investing carry inherent risk, including the risk of loss of capital, and that you act on this information entirely at your own discretion and risk. BG Trading recommends you obtain independent, licensed financial and taxation advice before making any investment decision.
BG Trading Australia | ACN 161943228 | Licence 4901880 | www.bgtrading.com.au